• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

门静脉高压症时肝外血管舒张的机制。

Mechanisms of extrahepatic vasodilation in portal hypertension.

作者信息

Hennenberg M, Trebicka J, Sauerbruch T, Heller J

机构信息

Department of Internal Medicine I, University of Bonn, Sigmund-Freud-Str. 25, D-53105 Bonn, Germany.

出版信息

Gut. 2008 Sep;57(9):1300-14. doi: 10.1136/gut.2007.144584. Epub 2008 Apr 29.

DOI:10.1136/gut.2007.144584
PMID:18445644
Abstract

In liver cirrhosis, abnormal persistent extrahepatic vasodilation leads to hyperdynamic circulatory dysfunction which essentially contributes to portal hypertension. Since portal hypertension is a major factor in the development of complications in cirrhosis, the mechanisms underlying this vasodilation are of paramount interest. Extensive studies performed in cirrhotic patients and animals revealed that this vasodilation is associated on the one hand with enhanced formation of vasodilators, and on the other hand with vascular hyporesponsiveness to vasoconstrictors. The latter phenomenon has been termed "vascular hypocontractility". It is caused by a combination of different mechanisms and factors described in this review.

摘要

在肝硬化中,异常持续的肝外血管扩张导致高动力循环功能障碍,这是门静脉高压的主要成因。由于门静脉高压是肝硬化并发症发生发展的主要因素,这种血管扩张的潜在机制备受关注。对肝硬化患者和动物进行的大量研究表明,这种血管扩张一方面与血管扩张剂生成增加有关,另一方面与血管对血管收缩剂反应性降低有关。后一种现象被称为“血管收缩功能减退”。它是由本综述中描述的多种不同机制和因素共同作用引起的。

相似文献

1
Mechanisms of extrahepatic vasodilation in portal hypertension.门静脉高压症时肝外血管舒张的机制。
Gut. 2008 Sep;57(9):1300-14. doi: 10.1136/gut.2007.144584. Epub 2008 Apr 29.
2
Hemodynamic changes in splanchnic blood vessels in portal hypertension.门静脉高压时内脏血管的血流动力学变化
Anat Rec (Hoboken). 2008 Jun;291(6):699-713. doi: 10.1002/ar.20667.
3
The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension.分子:门静脉高压症时内脏循环和体循环中观察到的动脉血管舒张机制
J Clin Gastroenterol. 2007 Nov-Dec;41 Suppl 3:S288-94. doi: 10.1097/MCG.0b013e3181468b4c.
4
Molecular Mechanisms Leading to Splanchnic Vasodilation in Liver Cirrhosis.肝硬化时导致内脏血管扩张的分子机制
J Vasc Res. 2017;54(2):92-99. doi: 10.1159/000462974. Epub 2017 Apr 13.
5
Splanchnic and systemic vasodilation: the experimental models.内脏和全身血管舒张:实验模型
J Clin Gastroenterol. 2007 Nov-Dec;41 Suppl 3:S272-87. doi: 10.1097/MCG.0b013e318157cb57.
6
Pathophysiology of portal hypertension.门静脉高压的病理生理学
Gastroenterol Clin North Am. 1992 Mar;21(1):1-14.
7
Pharmacological treatment of portal hypertension.门静脉高压症的药物治疗
Curr Opin Investig Drugs. 2001 Oct;2(10):1407-13.
8
Splanchnic and systemic vasodilatation: the patient.内脏和全身血管舒张:患者
J Clin Gastroenterol. 2007 Nov-Dec;41 Suppl 3:S266-71. doi: 10.1097/MCG.0b013e3181576d1a.
9
Hemodynamics in the isolated cirrhotic liver.离体肝硬化肝脏的血流动力学
J Clin Gastroenterol. 2007 Nov-Dec;41 Suppl 3:S254-8. doi: 10.1097/MCG.0b013e318150d3b5.
10
Pathophysiology of portal hypertension.门静脉高压的病理生理学
J Physiol Pharmacol. 2008 Aug;59 Suppl 2:231-8.

引用本文的文献

1
Cirrhotic Cardiomyopathy: Bridging Hepatic and Cardiac Pathophysiology in the Modern Era.肝硬化心肌病:现代肝脏与心脏病理生理学的桥梁
J Clin Med. 2025 Aug 25;14(17):5993. doi: 10.3390/jcm14175993.
2
Silencing of Rac1 and Arf6 reduces time-dependent and carbachol-induced contractions, proliferation, survival and growth in human bladder smooth muscle cells.Rac1和Arf6基因沉默可减少人膀胱平滑肌细胞中随时间变化的以及由卡巴胆碱诱导的收缩、增殖、存活和生长。
World J Urol. 2025 May 7;43(1):279. doi: 10.1007/s00345-025-05652-y.
3
The application of computational fluid dynamics in hepatic portal vein haemodynamics research: a narrative review.
计算流体动力学在肝门静脉血流动力学研究中的应用:一篇叙述性综述。
Quant Imaging Med Surg. 2025 Mar 3;15(3):2605-2620. doi: 10.21037/qims-24-1593. Epub 2025 Feb 26.
4
The Contemporary Role of Speckle Tracking Echocardiography in Cirrhotic Cardiomyopathy.斑点追踪超声心动图在肝硬化性心肌病中的当代作用
Life (Basel). 2024 Jan 25;14(2):179. doi: 10.3390/life14020179.
5
Lymphocyte-Specific Protein 1 Regulates Expression and Stability of Endothelial Nitric Oxide Synthase.淋巴细胞特异性蛋白 1 调节内皮型一氧化氮合酶的表达和稳定性。
Biomolecules. 2024 Jan 15;14(1):111. doi: 10.3390/biom14010111.
6
β-Blockers in Hepatosplenic Schistosomiasis: A Narrative Review.β-受体阻滞剂在肝脾血吸虫病中的应用:一篇叙述性综述。
Am J Trop Med Hyg. 2023 Nov 6;109(6):1213-1219. doi: 10.4269/ajtmh.23-0437. Print 2023 Dec 6.
7
Organ-specific off-target effects of Pim/ZIP kinase inhibitors suggest lack of contractile Pim kinase activity in prostate, bladder, and vascular smooth muscle.Pim/ZIP 激酶抑制剂的组织特异性脱靶效应表明前列腺、膀胱和血管平滑肌中不存在收缩性 Pim 激酶活性。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Feb;397(2):1219-1231. doi: 10.1007/s00210-023-02664-6. Epub 2023 Sep 1.
8
Close Relationship between Systemic Arterial and Portal Venous Pressure in an Animal Model with Healthy Liver.健康肝脏动物模型中系统性动脉压与门静脉压的密切关系。
Int J Mol Sci. 2023 Jun 9;24(12):9963. doi: 10.3390/ijms24129963.
9
Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003.通过沉默NUAK1和-2以及使用推测的NUAK抑制剂HTH01-015和WZ4003抑制人前列腺基质细胞的生长和收缩。
Front Pharmacol. 2023 Apr 28;14:1105427. doi: 10.3389/fphar.2023.1105427. eCollection 2023.
10
Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?肝硬化患者使用β受体阻滞剂:务实还是求全?
Front Med (Lausanne). 2023 Jan 9;9:1100966. doi: 10.3389/fmed.2022.1100966. eCollection 2022.